Gastric Cancer Global Market Report 2025

Gastric cancer is a malignant tumor that begins in the stomach lining, often starting in the mucosa, the innermost layer of the stomach. If left untreated, it can spread to deeper layers, surrounding tissues, or distant organs. Common risk factors for the disease include chronic infection with Helicobacter pylori, smoking, heavy alcohol consumption, an unhealthy diet, and genetic factors.

The main types of gastric cancers include adenocarcinoma, lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others. Adenocarcinoma, the most prevalent type, originates in the glandular cells of the stomach lining. Diagnosis is typically made through endoscopy, biopsy, imaging tests, exploratory surgery, and other methods. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, palliative care, and more. These treatments are distributed through various channels, including hospital pharmacies, specialty and retail pharmacies, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The gastric cancer market research report is one of a series of new reports from The Business Research Company that provides gastric cancer market statistics, including gastric cancer industry global market size, regional shares, competitors with a gastric cancer market share, detailed gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer industry. This gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer market size has grown rapidly in recent years. It will grow from $3.17 billion in 2024 to $3.64 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to rising geriatric population, increasing healthcare awarness, increasing genetic mutations, rising adoption of unhealthy lifestyles, growing awarness about cancer.

The gastric cancer market size is expected to see rapid growth in the next few years. It will grow to $6.37 billion in 2029 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to increasing obesity, growing government initiatives, increasing healthcare investments, rising demand for oral drugs, increasing number of cancer treatment facilities. Major trends in the forecast period include combination chemotherapy, product expansion, robotic-assisted surgery, targeted therapies, strategic collabration, advanced diagnostic tools.

The forecast of 15.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology outcomes by inflating prices of HER2-targeted therapies and laparoscopic gastrectomy devices developed in South Korea and Germany, resulting in delayed treatment initiation and higher cancer care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing rates of obesity are expected to drive the expansion of the gastric cancer market in the future. Obesity is a medical condition characterized by excessive body fat, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health complications. The increase in obesity rates can be attributed to factors such as poor dietary habits, lack of exercise, sedentary lifestyles, environmental influences, and genetic factors. Excess body fat, especially visceral fat around the abdomen, is linked to an elevated risk of developing gastric cancer. Obesity causes chronic inflammation and metabolic imbalances, both of which are associated with cancer development, thereby contributing to a higher demand for gastric cancer treatments. For example, the World Health Organization reported in March 2024 that approximately 1 in 8 people globally were living with obesity in 2022. Around 2.5 billion adults aged 18 and older were considered overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 were overweight, and more than 390 million children and adolescents aged 5-19 were overweight, including 160 million living with obesity. As a result, rising obesity rates are fueling the demand for gastric cancer treatments.

Leading companies in the gastric cancer market are focused on developing advanced solutions, such as companion diagnostic assays, to ensure personalized treatment. Companion diagnostic assays are tests that identify patients likely to benefit from specific treatments based on certain biomarkers. In October 2024, F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland, received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA CLDN18 (43-14A) RxDx Assay. This was the first immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by detecting CLDN18 protein variants, particularly CLDN18.2. This test utilizes the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, advancing personalized healthcare and expanding treatment options for gastric and GEJ adenocarcinoma patients.

In June 2022, Panbela Therapeutics Inc., a US-based biopharmaceutical company, acquired Cancer Prevention Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Panbela Therapeutics to diversify its pipeline and address multiple therapeutic areas. The deal adds four clinical-stage assets, including two late-stage registration assets, enhancing the combined entity's potential. This strategic move strengthens Panbela's position in high-potential therapeutic areas. Cancer Prevention Pharmaceuticals Inc. is a biotechnology company in the US that develops therapeutics for gastric cancer treatment.

Major players in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., and AROG Pharmaceuticals Inc.

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric cancer market consists of revenues earned by entities by providing services such as cancer screening and early detection, genetic testing, personalized treatment planning, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer market also includes sales of chemotherapeutic drugs, radiation therapy equipment, nutritional support products, surgical tools, and instruments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastric cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types
• 2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis
• 3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments
• 4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma
• 2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma
• 3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST
• 4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3
• 5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors
• Companies Mentioned: F. Hoffmann La Roche Ltd.; Merck And Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol Myers Squibb Company; Abbott Laboratories; Novartis AG; GlaxoSmithKline Plc; Eli Lilly and Company; Amgen Inc.; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Eisai Co. Ltd.; Ipsen Biopharmaceuticals Inc.; Ono Pharmaceutical Co. Ltd.; Samsung Biologics Co. Ltd.; Celltrion Healthcare Co. Ltd.; Biocon Limited; Hanmi Pharmaceuticals; Mylan N.V.; Taiho Oncology Inc.; Hikma Pharmaceuticals PLC; Taiho Pharmaceuticals Co. Ltd.; AROG Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.